Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Monoclonal antibodies (mAbs) targeting calcitonin-gene-related peptide (CGRP) or its receptor (anti-CGRP-R) have been widely administered to patients with migraine who show inadequate responses to preventive medications. Among patients in whom a particular anti-CGRP-R mAb is ineffective, switching between different anti-CGRP-R mAbs can be the next option. Few studies have investigated treatment outcomes for antibody switching, especially between mAbs with the same target of the CGRP ligand. We aimed to determine the treatment outcome after switching between two anti-CGRP mAbs (galcanezumab to fremanezumab). Methods We identified migraine patients in a prospective headache clinic registry who received galcanezumab for ≥3 months and were switched to fremanezumab for a further ≥3 months at a single university hospital. We defined a treatment response as a ≥50% reduction in the number of days with a moderate or severe headache at the third month of treatment relative to baseline. The treatment response after switching to fremanezumab was compared with the initial treatment response to galcanezumab. Results Among 21 patients identified in the registry, 7 (33.3%) were initial responders to galcanezumab. After switching to fremanezumab, 7 (33.3%) showed a treatment response. The treatment response rate was 28.6% in the initial responders and 71.4% in the nonresponders to galcanezumab (p>0.999). Conclusions Switching between anti-CGRP mAbs (galcanezumab to fremanezumab) yielded a treatment outcome comparable to that reported previously when switching from an anti- CGRP-R mAb (erenumab) to an anti-CGRP mAb (galcanezumab or fremanezumab). The treatment response to fremanezumab seems to be independent of the prior treatment response to galcanezumab. Our findings suggest that switching to another anti-CGRP mAb can be considered when a particular anti-CGRP mAb is ineffective or intolerable.
Abstract
Background and Purpose Monoclonal antibodies (mAbs) targeting calcitonin-gene-related peptide (CGRP) or its receptor (anti-CGRP-R) have been widely administered to patients with migraine who show inadequate responses to preventive medications. Among patients in whom a particular anti-CGRP-R mAb is ineffective, switching between different anti-CGRP-R mAbs can be the next option. Few studies have investigated treatment outcomes for antibody switching, especially between mAbs with the same target of the CGRP ligand. We aimed to determine the treatment outcome after switching between two anti-CGRP mAbs (galcanezumab to fremanezumab). Methods We identified migraine patients in a prospective headache clinic registry who received galcanezumab for ≥3 months and were switched to fremanezumab for a further ≥3 months at a single university hospital. We defined a treatment response as a ≥50% reduction in the number of days with a moderate or severe headache at the third month of treatment relative to baseline. The treatment response after switching to fremanezumab was compared with the initial treatment response to galcanezumab. Results Among 21 patients identified in the registry, 7 (33.3%) were initial responders to galcanezumab. After switching to fremanezumab, 7 (33.3%) showed a treatment response. The treatment response rate was 28.6% in the initial responders and 71.4% in the nonresponders to galcanezumab (p>0.999). Conclusions Switching between anti-CGRP mAbs (galcanezumab to fremanezumab) yielded a treatment outcome comparable to that reported previously when switching from an anti- CGRP-R mAb (erenumab) to an anti-CGRP mAb (galcanezumab or fremanezumab). The treatment response to fremanezumab seems to be independent of the prior treatment response to galcanezumab. Our findings suggest that switching to another anti-CGRP mAb can be considered when a particular anti-CGRP mAb is ineffective or intolerable.
참고문헌 (23)
- Edvinsson L, "CGRP as the target of new migraine therapies-successful translation from bench to clinic", Nat Rev Neurol, 14, pp.338~350 (2018)
- Bigal ME, "Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine : a multicentre, randomised, double-blind, placebo-controlled, phase 2b study", Lancet Neurol, 14, pp.1091~1100 (2015)
- Dodick DW, "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine : a randomised, double-blind, placebo-controlled, exploratory phase 2trial", Lancet Neurol, 13, pp.1100~1107 (2014)
- Dodick DW, "Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine : a phase 2, randomised, double-blind, placebo-controlled study", Lancet Neurol, 13, pp.885~892 (2014)
- Sun H, "Safety and efficacy of AMG 334 for prevention of episodic migraine : a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet Neurol, 15, pp.382~390 (2016)
- Alex A, "Safety and tolerability of 3 CGRP monoclonal antibodies in practice : a retrospective cohort study", Headache, 60, pp.2454~2462 (2020)
- Ferrari MD, "Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes(FOCUS) : a randomised, double-blind, placebo-controlled, phase 3b trial", Lancet, 394, pp.1030~1040 (2019)
- Reuter U, "Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful : a randomised, double-blind, placebocontrolled, phase 3b study", Lancet, 392, pp.2280~2287 (2018)
- Iannone LF, "Switching anti-CGRP(R)monoclonal antibodies in multiassessed non-responder patients and implications for ineffectiveness criteria : a retrospective cohort study", Cephalalgia, 43, pp.1~11 (2023)
- Overeem LH, "Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine : a multi-center retrospective cohort study", Cephalalgia, 42, pp.291~301 (2022)
- Ihara K, "Switching between anti-calcitonin gene-related peptide monoclonal antibodies : a comparison of monthly and quarterly dosing", J Neurol Sci, 453, pp.120811~ (2023)
- Headache Classification Committee of the International Headache Society(IHS), "The International Classification of Headache Disorders, 3rd edition", Cephalalgia, 38, pp.1~211 (2018)
- Detke HC, "Galcanezumab in chronic migraine : the randomized, double-blind, placebo-controlled REGAIN study", Neurology, 91, pp.e2211~e2221 (2018)
- Silberstein SD, "Fremanezumab for the preventive treatment of chronic migraine", N Engl J Med, 377, pp.2113~2122 (2017)
- Tepper S, "Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised, double-blind, placebo-controlled phase 2trial", Lancet Neurol, 16, pp.425~434 (2017)
- Kielbasa W, "A new era for migraine : pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody", Cephalalgia, 39, pp.1284~1297 (2019)
- Argyriou AA, "Predictors of response to fremanezumab in migraine patients with at least three previous preventive failures : post hoc analysis of a prospective, multicenter, real-world Greek registry", J Clin Med, 12, pp.3218~ (2023)
- Barbanti P, "Fremanezumab in the prevention of high-frequency episodic and chronic migraine : a 12-week, multicenter, real-life, cohort study(the FRIEND study)", J Headache Pain, 23, pp.46~ (2022)
- Nowaczewska M, "Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine—a real-life study", Front Neurol, 13, pp.895476~ (2022)
- di Cola FS, "An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor", Eur J Neurol, 30, pp.1764~1773 (2023)
- Silberstein S, "Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults", Cephalalgia, 28, pp.484~495 (2008)
- Straube A, "Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway : a subgroup analysis of the Finesse Study", J Headache Pain, 24, pp.59~ (2023)
- Kaltseis K, "Monoclonal antibodies against CGRP(R) : non-responders and switchers : real world data from an austrian case series", BMC Neurol, 23, pp.174~ (2023)